ImmunoGen Jobs & Careers

9 jobs

ImmunoGen
Who We Are ImmunoGen, Inc. develops targeted anticancer therapeutics. Our antibody-drug-conjugate (ADC) technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells; we have also developed antibodies with anticancer activity of their own. The first product with ImmunoGen's ADC technology is Roche's Kadcyla®. ImmunoGen has three wholly owned pr...

ImmunoGen
Who We Are ImmunoGen, Inc. develops targeted anticancer therapeutics. Our antibody-drug-conjugate (ADC) technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells; we have also developed antibodies with anticancer activity of their own. The first product with ImmunoGen's ADC technology is Roche's Kadcyla®. ImmunoGen has three wholly owned pr...

ImmunoGen
Who We Are ImmunoGen, Inc. develops targeted anticancer therapeutics. Our antibody-drug-conjugate (ADC) technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells; we have also developed antibodies with anticancer activity of their own. The first product with ImmunoGen's ADC technology is Roche's Kadcyla®. ImmunoGen has three wholly owned pr...

ImmunoGen
Who We Are ImmunoGen, Inc. develops targeted anticancer therapeutics. Our antibody-drug-conjugate (ADC) technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells; we have also developed antibodies with anticancer activity of their own. The first product with ImmunoGen's ADC technology is Roche's Kadcyla®. ImmunoGen has three wholly owned pr...

ImmunoGen
Who We Are ImmunoGen, Inc. develops targeted anticancer therapeutics. Our antibody-drug-conjugate (ADC) technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells; we have also developed antibodies with anticancer activity of their own. The first product with ImmunoGen's ADC technology is Roche's Kadcyla®. ImmunoGen has three wholly owned pr...

ImmunoGen
Who We Are ImmunoGen, Inc. develops targeted anticancer therapeutics. Our antibody-drug-conjugate (ADC) technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells; we have also developed antibodies with anticancer activity of their own. The first product with ImmunoGen's ADC technology is Roche's Kadcyla®. ImmunoGen has three wholly owned pr...

ImmunoGen
Who We Are ImmunoGen, Inc. develops targeted anticancer therapeutics. Our antibody-drug-conjugate (ADC) technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells; we have also developed antibodies with anticancer activity of their own. The first product with ImmunoGen's ADC technology is Roche's Kadcyla®. ImmunoGen has three wholly owned pr...

ImmunoGen
Who We Are ImmunoGen, Inc. develops targeted anticancer therapeutics. Our antibody-drug-conjugate (ADC) technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells; we have also developed antibodies with anticancer activity of their own. The first product with ImmunoGen's ADC technology is Roche's Kadcyla®. ImmunoGen has three wholly owned pr...

ImmunoGen
Who We Are ImmunoGen, Inc. develops targeted anticancer therapeutics. Our antibody-drug-conjugate (ADC) technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells; we have also developed antibodies with anticancer activity of their own. The first product with ImmunoGen's ADC technology is Roche's Kadcyla®. ImmunoGen has three wholly owned pr...